home / stock / ancn / ancn news

ANCN News and Press, Chemomab Therapeutics From 11/15/19

Stock Information
Company Name: Chemomab Therapeutics
Stock Symbol: ANCN
Market: NYSE
Website: chemomab.com
Menu
ANCN ANCN Quote ANCN Short ANCN News ANCN Articles ANCN Message Board
Get ANCN Alerts

News, Short Squeeze, Breakout and More Instantly...
ANCN - Anchiano Therapeutics EPS misses by $0.25

Anchiano Therapeutics (NASDAQ: ANCN ): Q3 GAAP EPS of -$0.43 misses by $0.25 . cash and cash equivalents of $23.2M. Press Release More news on: Anchiano Therapeutics Ltd, Earnings news and commentary, Healthcare stocks news, ,

ANCN - Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today reported financial results for its third quarter and nine mont...

ANCN - Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program

CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a biopharmaceutical company focused on discovery and development of targeted therapies to treat cancer, today announced the discontinuatio...

ANCN - Anchiano Therapeutics Chairman Stephen Hoffman Steps Down from Board

CAMBRIDGE, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a pivotal-stage biopharmaceutical company focused on the discovery and development of targeted therapies to treat cancer, today announced ...
ANCN - Anchiano Therapeutics Enters into An Exclusive Option To License Agreement for Novel Pan-RAS Inhibitor and PDE10/?-catenin Inhibitor Programs

Anchiano will make an upfront payment in exchange for the option to in-license at any time through obtaining an Investigational New Drug (IND) designation Company also provides update on accrual to its ongoing pivotal Phase 2 Codex trial Anchiano to hold a call on Tuesday, Septem...

ANCN - Anchiano Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

CAMBRIDGE, Mass., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that Frank Haluska, M.D., Ph.D., ...

ANCN - Anchiano Therapeutics to Present at the Baird 2019 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that Frank Haluska, M.D., Ph.D., ...
ANCN - Anchiano Therapeutics EPS beats by $0.12

Anchiano Therapeutics (NASDAQ: ANCN ): Q2 GAAP EPS of -$0.05 beats by $0.12 . More news on: Anchiano Therapeutics Ltd, Earnings news and commentary, Healthcare stocks news, , Read more ...

ANCN - Anchiano Therapeutics Reports Second Quarter 2019 Financial Results

CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today reported financial results for its second qu...

ANCN - Anchiano Therapeutics Delists Ordinary Shares from the Tel Aviv Stock Exchange

CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a pivotal-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today announced that it completed the process to v...
Previous 10 Next 10